Image Not Found On Media Library
  • HOME
  • ABOUT MORSE
    • The Team
    • Careers
  • SERVICES
    • Our Services
      • Comprehensive Market Access Launch Strategy
      • Market Access Landscape Analysis
      • HTA Planning and Reimbursement Evidence Strategy
      • Negotiation & Stakeholder Engagement Strategy
      • Portfolio & Life Cycle Strategy
      • Expert-Led Training & Customized Workshops
  • REPORTS
    • NEW – Pre-Order CRaFT 2025
    • 2024 CRaFT Report
    • DRD Market Access Trends & Insights
    • Oncology Market Access Trends & Insights
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US
logo-top-r
Image Not Found On Media Library
  • HOME
  • ABOUT MORSE
    • The Team
    • Careers
  • SERVICES
    • Our Services
      • Comprehensive Market Access Launch Strategy
      • Market Access Landscape Analysis
      • HTA Planning and Reimbursement Evidence Strategy
      • Negotiation & Stakeholder Engagement Strategy
      • Portfolio & Life Cycle Strategy
      • Expert-Led Training & Customized Workshops
  • REPORTS
    • NEW – Pre-Order CRaFT 2025
    • 2024 CRaFT Report
    • DRD Market Access Trends & Insights
    • Oncology Market Access Trends & Insights
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US

pCPA Closing in on 300 Completed Negotiations

February 13, 2020
-
Market Access News
-
Posted by MORSE - 2 min read.

pan-Canadian Pharmaceutical Alliance (pCPA): January 2020 Trends and Insights

 

The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the January 31, 2020 status of brand negotiations. Highlights since the last update include:

● 2 products completed CADTH review, for a total of 9 files under consideration;
● 4 products initiated pCPA negotiations, for a total of 34 active negotiations;
● 2 negotiations completed for a total of 297 completed negotiations;
● No negotiations closed, for a total of 48 closed negotiations; and
● No files closed without negotiations, for a total of 73 declined negotiations.

 

Files Under pCPA Consideration

 

2 new drug products received a CDEC recommendation or pERC notification to implement in January 2020, for a total of approximately 9 products* under pCPA Consideration.

 

Brand Name Generic Name Manufacturer Indication Recommendation
Keytruda Pembrolizumab Merck Canada Squamous NSCLC Conditional
Baqsimi glucagon Eli Lilly Canada Inc. Severe hypoglycemic reactions Conditional

*Keytruda was initiated in January 2020 and therefore, was not included in the under consideration count.

 

Negotiation Initiation

 

The pCPA initiated 4 new negotiations since the last update, for a total of 34 active negotiations.

 

Brand Name Generic Name Manufacturer Indication CADTH Date Time to Initiate
Cimzia Certolizumab pegol UCB Moderate to severe plaque psoriasis 20 Nov 19 56 days
Admelog Insulin lispro Sanofi Type 1 and Type 2 Diabetes N/A N/A
Keytruda Pembrolizumab Merck Squamous NSCLC 20 Jan 20 0 days
Xultophy Insulin degludec/liraglutide Novo Nordisk Type 2 Diabetes 24 Oct 19 83 days

*Negotiation initiation and completion/closed date assumed to be mid-month; approximate calendar days calculated.

 

Signals Decoded:

Keytruda is now under active negotiations for 5 indications while Cimzia re-enters pCPA negotiations having previously completed an agreement for the Ankylosing Spondylitis and Psoriatic Arthritis indications. While two previous attempts to reach an agreement on Victoza (liraglutide) were unsuccessful, the pCPA will now consider liraglutide in combination with insulin degludec (Tresiba), for which it completed an agreement in July 2018. Finally, negotiations have been initiated for the biosimilar Admelog, which remains under active review by INESSS.

 

 

Completed

 

The pCPA completed 2 negotiations since the last update for a total of 297 completed negotiations.

 

Brand Name Generic Name Manufacturer Indication Initiated Duration*
Brineura Cerliponase alfa Biomarin Neuronal ceroid lipofuscinosis type 2 Mar 19 306 days
Folotyn Pralatrexate Servier Peripheral T-cell lymphoma Jun 19 204 days

*Negotiation initiation and completion/closed date assumed to be mid-month; approximate calendar days calculated.

 

 

To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.

 

Share
Tags
CADTH
CDEC
Oncology
Pan Canadian Pharmaceutical Alliance
pCPA
pCPAO
pERC
← PREVIOUS POST
MORSE Consulting Strengthens HTA Strategy and Payer Expertise
NEXT POST →
MORSE Consulting Releases its Third Annual pCPA Year in Review Infographic (2019 Edition)

Contact Us

MORSE Consulting Inc.

Toronto | Ottawa, Canada

+1-647-717-3179 (Toronto)

+1-613-864-8645 (Ottawa)

info@morseconsulting.ca

Pre-Order 2025 Report

2025 Canadian Reimbursement and Forecasting Timelines Report

Social
Connect & Follow:
Newsletter – MORSE Signals
Sign up for our free e-mail newsletter service and receive timely and relevant updates related to the emerging developments in the Canadian pharmaceutical reimbursement landscape.

Sign Up
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2023 MORSE Consulting Inc. All rights reserved. | Site by Directica Media
pCPA Closing in on 300 Completed Negotiations
Learn More
Learn More